Abbott India Q4FY25 Results Overview

Net Profit: ₹367 crore, up 28% YoY – reflecting strong operational performance. Revenue: ₹1,605 crore, up 11.5% YoY. Full-Year FY25 Revenue: ₹6,409 crore (vs ₹5,849 crore in FY24) – strong annual growth. Growth Drivers: Expanding pharma portfolio. Strategic focus on chronic therapies. Rising healthcare awareness and spending in India. Strong presence in branded generics. Operational Strength: EBITDA up 30% YoY, with margin improvement to 26.7% – a big positive. Shows excellent cost discipline and leverage on fixed costs. ⚠️ Concerns & Risks High Valuation: PE ratio is above sector average, implying limited room for valuation expansion. Investors paying a premium for quality, which adds risk in volatile phases. Regulatory Hurdles: Price control by NPPA on essential medicines can impact margins. Any policy tightening can affect top-line growth.